Compare · BXRX vs PGNY
BXRX vs PGNY
Side-by-side comparison of Baudax Bio Inc. (BXRX) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BXRX and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PGNY is the larger of the two at $1.97B, about 133.9x BXRX ($14.7M).
- PGNY has hit the wire 22 times in the past 4 weeks while BXRX has been quiet.
- PGNY has more recent analyst coverage (25 ratings vs 0 for BXRX).
- Company
- Baudax Bio Inc.
- Progyny Inc.
- Price
- $0.18+5.03%
- $25.02-0.38%
- Market cap
- $14.7M
- $1.97B
- 1M return
- -
- +32.25%
- 1Y return
- -
- +13.81%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 0
- 22
- Recent ratings
- 0
- 25
Baudax Bio Inc.
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest BXRX
- SEC Form 8-K filed by Baudax Bio Inc.
- SEC Form 25-NSE filed by Baudax Bio Inc.
- SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)
- SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)
- Baudax Bio Inc. filed SEC Form 8-K: Other Events
- CORRECTION: BioCryst Pharmaceuticals Ticker is "BCRX
- BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities
- SEC Form 424B3 filed by Baudax Bio Inc.
- SEC Form 10-Q filed by Baudax Bio Inc.
- SEC Form NT 10-Q filed by Baudax Bio Inc.
Latest PGNY
- CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 158 shares and sold $7,310 worth of shares (279 units at $26.20) as part of a pre-agreed trading plan, decreasing direct ownership by 0.55% to 78,626 units (SEC Form 4) (withholding tax)
- Director Scott Cheryl exercised 14,667 shares at a strike of $13.00, covered exercise/tax liability with 7,228 shares and sold $196,278 worth of shares (7,439 units at $26.39) (SEC Form 4)
- Chief Product Officer Clapp Geoffrey sold $39,137 worth of shares (1,530 units at $25.58), exercised 12,909 shares at a strike of $20.91 and covered exercise/tax liability with 11,379 shares (SEC Form 4) (for tax liability)
- EVP, GC Swartz Allison covered exercise/tax liability with 1,352 shares and sold $61,053 worth of shares (2,398 units at $25.46) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 85,191 units (SEC Form 4) to cover withholding tax
- Director Gordon Kevin K sold $137,445 worth of shares (5,500 units at $24.99), disposed of 2,526 shares and acquired 2,526 shares, decreasing direct ownership by 54% to 6,792 units (SEC Form 4)
- New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System
- SEC Form 144 filed by Progyny Inc.
- Progyny Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Bierbower Elizabeth D was granted 5,660 shares (SEC Form 4)
- Director Dean Lloyd H was granted 6,792 shares, increasing direct ownership by 34% to 26,519 units (SEC Form 4)